{"id":"W4411333831","doi":"10.1002/hon.70093_50","title":"50 | FIXED‐DURATION OUTPATIENT SUBCUTANEOUS MOSUNETUZUMAB + POLATUZUMAB VEDOTIN SHOWS ROBUST EFFICACY IN A PHASE II STUDY OF RELAPSED/REFRACTORY POST‐BTKi MANTLE CELL LYMPHOMA","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital","funders":"Science and Engineering Research Board; BeiGene; F. Hoffmann-La Roche; Genentech; AstraZeneca; Celgene; Gilead Sciences; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); Mantle cell lymphoma; Internal medicine; Lymphoma; Oncology; Materials science; Composite material","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002146354,0.0003883369,0.001419356,0.0003503137,0.0001486296,0.00001199371,0.0001994775,0.0005406371,0.0002574386],"category_scores_gemma":[0.0003803858,0.0002933501,0.0002034377,0.0004299509,0.0001413704,0.00006061701,0.0002226605,0.0002656344,0.00004598394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001298117,"about_ca_system_score_gemma":0.0005699532,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003531046,"about_ca_topic_score_gemma":0.0004034452,"domain_scores_codex":[0.9967846,0.0003573214,0.001303092,0.0007171333,0.0003360522,0.0005017628],"domain_scores_gemma":[0.997812,0.0008772244,0.0004128824,0.0005485108,0.0001710254,0.0001783373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.02976082,0.738319,0.1032015,0.0006982104,0.0008308748,0.01800712,0.009288543,0.0003895566,0.01275323,0.003223252,0.004318999,0.0792089],"study_design_scores_gemma":[0.3068354,0.3518779,0.2692854,0.0008845722,0.002219533,0.002910197,0.01381008,0.002520831,0.02072238,0.000300839,0.02712933,0.001503551],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909042,0.001205849,0.00002131234,0.0007262345,0.000346496,0.002102624,0.00001909609,0.0000895651,0.004584639],"genre_scores_gemma":[0.9980212,0.00009314763,0.0005396052,0.0005050706,0.00002888801,0.0002537441,0.0000975675,0.00002178292,0.0004389282],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3864411,"threshold_uncertainty_score":0.9999518,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02473748507732553,"score_gpt":0.3116219902016331,"score_spread":0.2868845051243075,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}